Gene-editing biotechs drop as cancer concerns weigh on CRISPR; Allergan's atogepant clears Phase 3 migraine test; BridgeBio launches new biotech to develop Alexion drug; 'Patient-focused' drug development guidance coming, FDA chief says
Learn how the industry is experiencing a digital disruption, impacting the entire spectrum of drug development. Senior pharma executives weigh in on how to advance the future of clinical trials. Read more
Shares in Editas, Intellia and others fell after two studies found CRISPR/Cas9 technology seems to work best in cells at higher risk of becoming cancerous.
But will the pharma's development strategy play out fast enough? A newly OK'd preventive drug from Novartis and Amgen could change the market, and similar drugs loom.
As more people research their health online, brands must understand their digital journey. This free report provides an in-depth look at the online behaviors of five major health condition groups.
The biotech parent company took a well-worn route in creating its latest subsidiary, back-stopping it with cash and building it around an acquired asset for an ultra-rare disease.
The plan calls for greater data transparency, as well as use of a Medicare heat map to pinpoint areas that can benefit from targeted safe prescribing efforts.
The last decade of biopharmaceutical dealmaking has seen peaks and valleys in activity, therapeutic areas that have fallen in and out of favor along with pace of innovation, and a sustained focus on the next "hot spot" with commercial value. Read the outlook for 2018 in the 10th annual Dealmakers' Intentions Study.
Our mission is to provide busy execs like you with an overview of the BioPharma industry in 60 seconds. BioPharma Dive is a product of Industry Dive. View other Industry Dive publications.
This email is optimized for display on mobile phones. BioPharma Dive is a product of Industry Dive, Inc.. 1575 Eye St NW, 4th Floor, Washington, DC 20005. We value your privacy. We won't share your email address with anyone else without your permission. This message was sent to [email protected]. You can unsubscribe or change which newsletters you receive anytime. See our full privacy policy.